Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04672733 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Study acronym: pHeNIx
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 27 sitesv24
  2. Re-verified, no change to tracked fieldsv23
  3. Study sites: 26 to 27v22
  4. Primary and study completion dates: Sep 2024 to Dec 2027 Study sites: 24 to 26v21 Show 1 more changeShow less
    • Study sites: 24 to 26
  5. Site details revised at 3 of 24 sitesv20
Show 18 earlier versionsHide 18 earlier versions
  1. Site details revised at 1 of 24 sitesv19
  2. Site details revised at 2 of 24 sitesv18
  3. Study sites: 22 to 24v17
  4. Study sites: 21 to 22v16
  5. Study sites: 20 to 21v15
  6. Site details revised at 1 of 20 sitesv14
  7. Site details revised at 3 of 20 sitesv13
  8. Study sites: 17 to 20v12
  9. Study sites: 18 to 17v11
  10. Study sites: 17 to 18 Start date changed from estimate of Jun 2022 to Jun 10, 2022v10 Show 1 more changeShow less
    • Start date changed from estimate of Jun 2022 to Jun 10, 2022
  11. Start date: May 2022 to Jun 2022 Site details revised at 6 of 17 sitesv9 Show 1 more changeShow less
    • Site details revised at 6 of 17 sites
  12. Trial status: Suspended to Recruiting Start date: Mar 2022 to May 2022 · Site details revised at 17 of 17 sitesv8 Show 2 more changesShow less
    • Start date: Mar 2022 to May 2022
    • Site details revised at 17 of 17 sites
  13. Study sites revised (17)v7 See this version in full on ClinicalTrials.gov ↗
  14. Eligibility criteria shortened, about 1 wordv6 See this version in full on ClinicalTrials.gov ↗
  15. Trial status: Not Yet Recruiting to Suspended Sponsor's reason: Suspended due to the COVID situationv5
  16. Primary and study completion dates: Sep 2023 to Sep 2024 Start date: Mar 2021 to Mar 2022v4 Show 1 more changeShow less
    • Start date: Mar 2021 to Mar 2022
  17. Re-verified, no change to tracked fieldsv3
  18. Start date: Dec 2020 to Mar 2021 Secondary endpoints revised (18)v2 Show 1 more changeShow less
    • Secondary endpoints revised (18)

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CSL Behring
30 trials monitored
See 2 trials at risk
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Trial Details
NCT Number NCT04672733
Lead Sponsor CSL Behring
Conditions Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov